

















1656Busulfan, Fludarabine, and Alemtuzumab As a Reduced
Toxicity Regimen for Children with Malignant and
Nonmalignant Diseases Improves Engraftment and
Graft-versus-Host Disease without Delaying Immune
Reconstitution
Jason Law,1 Morton J. Cowan,2 Christopher C. Dvorak,2 Lisa Musick,3 Janel R. Long-Boyle,3
Lee Ann Baxter-Lowe,4 Biljana Horn2For children receiving allogeneic hematopoietic stem cell transplants (HSCTs), the toxicity of the condition-
ing regimen and graft failure remain challenges. We previously reported that targeted i.v. busulfan, fludara-
bine, and rabbit anti-thymocyte globulin (rATG) decreased toxicity but had a graft failure rate of 21%. To
improve the engraftment rate, we replaced ATG with alemtuzumab, a monoclonal Ab targeting CD52.
Thirty-five children with malignant and nonmalignant diseases were enrolled in this phase II prospective
study. Twelve children had HLA-matched related donors (MRDs), 16 had 10 of 10, and 7 had 9 of 10 HLA
allele-matched unrelated donors (MUDs). Thirty-one of 34 evaluable patients (91%) achieved a durable en-
graftment. All 3 patients who rejected had a nonmalignant disease and received a MUD transplantation (2
mismatched at 1 antigen). Three patients died of a transplantation-related complication (9%6 5.2%). Seven
patients had disease relapse or progression, 2 of whom died. At a median follow-up of 35 months (range,
15-85 months), the event-free survival (EFS) was 61% 6 9.0% and the overall survival (OS) was 78% 6
7.5%. The median time to neutrophil recovery, B cell, and T cell reconstitution were 16 days, 3 months,
and 6 months, respectively. At 1 year, the median donor chimerism in whole blood, CD3, CD14/15, and
CD19 subsets were 97%, 87%, 100%, and 99%, respectively. Six patients (17% 6 6.6%) developed acute
graft-versus-host disease (aGVHD), only 2 of which were .grade II. Two patients (8% 6 5.4%) progressed
to chronic GVHD (cGVHD). These results suggest that replacement of rATG with alemtuzumab may im-
prove engraftment as well as decrease cGVHD rates without resulting in delays in immune reconstitution.
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6/j.bbmt.2012.05.006marrow stem cells, an allogeneic hematopoietic stem
cell transplant offers the best chance of a cure. Out-
comes range from 60% to 95% and depend upon dis-
ease, stem cell source, and patient condition at the time
of transplantation [1-4].
Our group has previously reported results of trans-
plantation after a reduced toxicity conditioning regi-
men with targeted i.v. busulfan, fludarabine, and
rabbit anti-thymocyte globulin (rATG) [5]. For pa-
tients undergoing a matched related donor (MRD) or
matched unrelated donor (MUD) transplantation, this
regimen was well-tolerated and provided an excellent
overall survival (OS) of 89% 6 7%. However, the rate
of graft failure (21%) remained an outstanding issue,
especially in recipients of HLA-mismatched grafts.
Alemtuzumab (Campath 1-H), a humanized
monoclonal Ab directed against CD52, induces effi-
cient complement mediated lysis and Ab-dependent
cellular cytotoxicity [6]. Alemtuzumab significantly
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(NK) cells known to play an important role in graft re-
jection [7]. Furthermore, alemtuzumab has a long half-
life and can be detected up to 56 days after infusion [8].
We, therefore, hypothesized that alemtuzumab may
reduce rejection. Studies published so far have shown
that alemtuzumab is well-tolerated, although few trials
have reported large pediatric cohorts [9,10].
We prospectively evaluated the use of targeted i.v.
busulfan, fludarabine, and alemtuzumab in a phase II
study of children receivingmatched or closelymatched
HCT for the treatment of nonmalignant diseases and
myeloid malignancies. We describe the engraftment
rate, chimerism, immune reconstitution, and toxicities
of this conditioning regimen.METHODS
Study Design
Enrollment of patients #21 years old in this pro-
spective phase II study conducted at the Benioff Chil-
dren’s Hospital, University of California San
Francisco, began in 2005 and reached the intended en-
rollment of 35 patients in 2010. Eligible patients in-
cluded those with marrow aplasia, bone marrow
(BM) failure syndromes, hemoglobinopathies, immu-
nodeficiencies, inborn errors of metabolism, and mye-
loid malignancies. Exclusion criteria included patients
with severe combined immunodeficiency (SCID) and
patients with poor cardiac, renal, or pulmonary func-
tion as characterized by pretransplantation evaluation.
The University of California San Francisco Commit-
tee on Human Research approved the study, and in-
formed consent was obtained from all participants or
their guardians.
Donors and Stem Cell Sources
Donors were selected based upon the best allele
match for HLA-A, HLA-B, HLA-C, DRB1, and DQ
high-resolution typing. Only 1 allele or antigen mis-
match was accepted. BM was the preferred stem cell
source, but peripheral blood stem cells (PBSCs) were
accepted if that was the donor’s preference. Related
umbilical cord blood was used only in conjunction
with BM. Stem cell products were fresh and unmanip-
ulated other than routine processing such as RBC
depletion in the setting of ABO incompatibility.
Conditioning Regimen
On day212, a 1 mg test dose of alemtuzumab was
delivered followed by 0.5 mg/kg (maximum dose5 15
mg) daily for 3 days (maximum total dose 5 46 mg).
Busulfan was administered i.v. every 6 hours from
day 29 to day 26 for 16 total doses. Fludarabine was
started on day 25 at a dose of 1.3 mg/kg daily for 4days if the patient was less than 12 kg. Otherwise, the
dose was 40 mg/m2 per dose. The hematopoietic
stem cells were infused on day 0. Granulocyte colony-
stimulating factor was started on day 15.
Busulfan Pharmacokinetics and Targeting
The pharmacokinetic (PK) analysis of busulfan
levels was performed as previously reported [5]. The
target steady-state concentration (Css) was 900 ng/
mL for patients with chronic myelogenous leukemia
(CML) in chronic phase, acute myelogenous leukemia
in first remission, and myelodysplastic syndrome
(MDS). The first 2 patients with hemophagocytic lym-
phohistiocytosis (HLH) had busulfan targeted to 900
ng/mL, but the 2 subsequent patients were targeted
to 600 ng/mL as our guidelines changed due to con-
cern for increased rates of sinusoidal obstructive syn-
drome (SOS) in patients with HLH. The initial
busulfan dose was determined after a test dose (0.5
mg/kg) given 1 to 2 days before starting conditioning.
A repeat PK study was done with the first full dose of
busulfan (day 29) and the dose changed if necessary
on dose 6 (day 28). If the busulfan dose was changed,
a repeat PK study was performed on dose 9 with a pos-
sible further dose change on dose 14 (day 27).
GVHD Prophylaxis
GVHD prophylaxis consisted of cyclosporine A
beginning as a continuous infusion on day 21 at 3
mg/kg/day and methotrexate at 15 mg/m2 on day 11
and 10 mg/m2 on days 13, 16, and 111, for MUDs.
In patients receiving matched related transplantations,
day 111 methotrexate was omitted.
Supportive Care
Lorazepam was used as seizure prophylaxis during
the administration of busulfan. N-acetylcysteine 100
mg/kg/dose (max dose 6 g) was given for SOS prophy-
laxis on day of admission to hematopoietic cell trans-
plant (HCT) and on days 11 and 12. Infection
prophylaxis included acyclovir, fluconazole, cotrima-
zole, and i.v. Ig until T and B cell immune reconstitu-
tion was established. Testing for cytomegalovirus
(CMV) and Epstein–Barr virus (EBV) by polymerase
chain reaction (PCR) was performed weekly at least
until day1100 and every 2 weeks until T cell reconsti-
tution.
Adverse Events and Stopping Criteria
All adverse events were graded per the Common
Terminology Criteria for Adverse Events v 3.0.
GVHD and SOS were graded according to published
criteria [11,12]. Adverse events were monitored for
stopping criteria and included: need for a second
transplantation within the first year of transplantation
in any 6 patients or $2 of the first 9 or $4 of the first
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or progressive host chimerism; treatment-related mor-
tality (TRM) occurring in $3 of the first 10 or $4 of
the first 20 or $5 of the first 30 patients; any death
judged to be related to alemtuzumab such as anaphy-
laxis or infections such as CMV or EBV.
Chimerism Testing
Peripheral blood chimerism studieswereperformed
by Q-PCR evaluation of differential short tandem
repeat DNA sequences, as previously described [13].
Chimerism analysis was performed on day 130. If
found to be a mixed chimera (\95% donor), engraft-
ment testing occurred monthly until 1 year posttrans-
plantation or until full donor chimerism was achieved,
whichever occurred first. Thereafter, testing occurred
every 3 months until 2 years posttransplantation. In-
creased frequency of chimerism testing occurred if
falling donor chimerism was found.
Donor lymphocyte infusion (DLI) was adminis-
tered for molecular disease relapse in CML, poor im-
mune reconstitution, and persistence of host
chimerism. For patients with malignancy, any level
of host chimerism present, despite rapid withdrawal
of immunosuppression, was an indication for DLI
[5,13]. In patients without malignancy, DLI was
given to those at risk for rejection defined as\70%
donor chimerism in whole blood or \50% in the
CD3 subset at 3 months posttransplantation. Initial
DLI dose for patients receiving a fully MRD trans-
plantation was 1  106/kg of CD31 cells and 1 
105/kg of CD31 cells for those receiving amismatched
related or MUD transplantation. Subsequent doses
were escalated per physician discretion.
Immune Studies and Reconstitution
Lymphocyte subsets (CD3, CD4, CD8, CD19,
and CD16/56) were measured before and after admin-
istration of alemtuzumab but before the infusion of bu-
sulfan. T and B cell function was measured every 3
months posttransplantation. The B cell reconstitution
was defined by IgM levels .50 mg/dL and isohemag-
glutinin titers$1:8. The T cell reconstitution was de-
fined as CD4.200 and a response to PHA stimulation
at least 50% of control.
Statistical Analysis
Patient characteristics and baseline transplantation-
related information was summarized using descriptive
statistics (mean, median, SE, minimum and maximum
for quantitative parameters, and frequency and pro-
portion for qualitative parameters). Survival was calcu-
lated using Kaplan-Meier statistics from time of
transplantation until analysis. Event-free survival
(EFS) was calculated from the day of transplantation
until disease progression, relapse, second transplanta-tion, or death. Continuous variables were compared
using a 2-tailed t test. Categorical variables were com-
pared using chi-squared analysis or Fisher exact test
when data were sparse, with 2-sided P values. Statisti-
cal analysis was performed on the SPSS statistical plat-
form version 19.0.0 (SPSS, Inc., Chicago, IL).RESULTS
Demographic data are summarized in Table 1. The
median age of our 35 patients was 7, with a range of
5 months to 20 years old. Nonmalignant diseases in-
cluded hemoglobinopathy (n 5 7), non-SCID immu-
nodeficiency (n 5 6), HLH (n 5 4), inborn error of
metabolism (n5 4), severe aplastic anemia (n5 3), con-
genital marrow failure syndromes (n 5 2), and severe
immune dysregulation/autoimmune disorders (n 5 4).
Malignant diagnoses included CML (n5 1), acute pro-
myelocytic leukemia (n5 1), andMDS (n5 3). Twelve
patients received a MRD transplantation, 16 received
a 10 of 10 MUD transplantation, whereas 7 received
a 9 of 10 MUD transplantation.
The stem cell source was BM in 20 patients and pe-
ripheral blood in 13 patients. One patient received BM
to augment cord blood cells from the same donor. Due
to poormobilization of allogeneic PBSCs, 1 patient re-
ceived both PBSCs and BM from the same donor. Pa-
tients receiving BM received a median of 5.756 1.9 
108 total viable nucleated cells/kg, whereas those re-
ceiving a PBSC transplantation received a median
CD341 stem cell dose of 6.24 6 1.1  106 CD341
cells/kg. Sustained donor engraftment was achieved
in 91% of evaluable patients, including 96% of pa-
tients receiving stem cells from fully matched donors,
and 71% of those receiving stem cells from mis-
matched donors. Three patients failed to engraft and
underwent subsequent transplantations. These 3 pa-
tients underwent transplantation for nonmalignant
diseases and all had received unrelated donor BM
grafts with 2mismatched at 1 antigen. One of these pa-
tients is alive and without evidence of disease.
Busulfan PK and Css
Busulfan Css data was available for both the test
dose and dose 1 in 29 of 35 patients. Css data obtained
with dose 9 of busulfan was available in 25 of 35 pa-
tients. The mean test dose (0.5 mg/kg) Css was 344
ng/mL (range, 199-661). For dose 1, the average
dose targeted to achieve a Css of 600 ng/mL in patients
with nonmalignant disorders was 0.9 mg/kg (range,
0.7-1.4) and yielded a mean Css of 576 ng/mL (range,
379-869). In patients with malignant diseases, the av-
erage dose aimed to achieve a Css of 900 ng/mL was
1.2 mg/kg (range, 1-1.3), resulting in a Css of 715
ng/mL (range, 581-829). Once steady state was
achieved in patients with nonmalignant disorders, the
Table 1. Patient Demographics
UPN Diagnosis Age, y Donor Source Cell Dose* GVHD Outcome F/U, mo
1046 Myasthenia gravis 14 MRD PB 4.96 None Alive and well 77
1070 Thalassemia 9 MRD BM & UCB 1.35BM, .42UCB None Alive and well 85
1101 CML without remission 16 MRD PB 5.00 N/A Alive after relapse 73
1126 Chronic granulomatous disease 1 MRD BM 8.10 None Alive and well 62
1137 Adrenoleukodystrophy 8 MRD PB 7.59 GIII aGVHD,
cGVHD
Died of disease progression 13
1176 Aplastic anemia 12 MRD BM & PB 5.64 None Alive and well 56
1211 PNH 12 MRD BM 6.42 None Alive after relapse 56
1279 Sickle cell anemia 9 MRD BM 8.31 None Alive and well 43
1285 Sickle cell anemia 11 MRD BM 6.72 None Alive and well 39
1306 MDS 7 MRD PB 7.07 None Alive after relapse 42
1331 HLH 11 MRD BM 5.19 None Died after relapse and 2nd BMT 32
1402 HLH 0 MRD BM 10.14 None Died of TRM: pulmonary disease 2
1051 Evan syndrome 5 MUD BM 4.00 None Died of TRM: hemorrhage 1
1078 Hyper-IgM syndrome 7 MUD BM 4.18 None Alive and well 31
1100 X-linked lymphoproliferative disease 2 MUD PB 8.01 None Alive and well 69
1104 Hurler syndrome 1 MUD BM 5.34 Grade II aGVHD Graft failure, alive after 2nd BMT 73
1139 Hyper-IgM syndrome 3 MUD PB 6.36 None Alive and well 41
1187 MDS 6 MUD BM 4.21 None Alive after relapse 57
1216 Aplastic anemia 8 MUD BM 3.21 None Alive and well 33
1254 Red cell aplasia 3 MUD BM 4.50 None Alive and well 15
1261 HLH 2 MUD BM 7.68 None Alive and well 47
1294 Combined immunodeficiency 5 MUD PB 6.69 None Alive and well 30
1322 Thalassemia 5 MUD PB 6.11 Grade I aGVHD Alive and well 19
1369 Thalassemia 17 MUD BM 4.54 None Alive and well 31
1388 Thalassemia 20 MUD PB 5.02 Grade II aGVHD,
cGVHD
Alive and well 16
1395 Chronic EBV infection 9 MUD PB 5.99 None Alive after relapse 25
1419 Thalassemia 14 MUD BM 2.52 None Alive and well 21
1428 HLH 1 MUD BM 3.70 None Alive and well 21
1079 MDS 1 MMUD PB 6.99 Grade II aGVHD Alive and well 78
1116 Adrenoleukodystrophy 12 MMUD PB 7.99 Grade IV aGVHD Died of TRM: infectious 5
1186 Wiskott-Aldrich syndrome 1 MMUD BM 6.41 None Alive and well 55
1245 Congenital neutropenia 9 MMUD BM 8.04 None Graft failure, died after 2nd BMT 3
1272 Acute promyelocytic leukemia 5 MMUD PB 5.18 None Alive and well 45
1333 X-linked lymphoproliferative disease 3 MMUD BM 6.16 None Alive and well 35
1336 Congenital erythropoietic porphyria 1 MMUD BM 6.17 None Graft rejection, died after 4th BMT 5
UPN indicates unique patient number; GVHD, graft-versus-host disease; F/U, follow-up; MRD, matched related donor; PB, peripheral blood; BM, bone
marrow; UCB, umbilical cord blood; CML, chronic myelogenous leukemia; N/A, not applicable; aGVHD, acute graft-versus-host disease; cGVHD,
chronic graft-versus-host disease; PNH, paroxysmal nocturnal hemoglobinuria; MDS, myelodysplastic syndrome; HLH, hemophagocytic lymphohistio-
cytosis; BMT, bonemarrow transplant; TRM, treatment-relatedmortality; MUD,matched unrelated donor; EBV, Epstein-Barr virus; MMUD, mismatched
unrelated donor.
*Cell dose for bone marrow and cord blood5N 108 nucleated cells/kg of recipient weight; cell dose for peripheral blood5N 106 CD34+ cells/kg
of recipient weight.
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0.5-1.3) and 765 ng/mL (range, 535-1091), respec-
tively. At steady state for patients with malignant dis-
eases, the average dose at dose 9 was 1.4 mg/kg
(range, 1.2-1.6), resulting in a mean Css of 1015 ng/
mL (range, 775-1253).Chimerism
The median percentage of donor cells in whole
blood and cell-subsets for the 31 patients who en-
grafted is illustrated in Figure 1 (censored at the time
of second transplantation [n 5 4]). The median donor
chimerism at 1 month was 99% 6 0.4% in whole
blood analysis and found to be 92% 6 2.0% at 24
months posttransplantation. Patients achieved an ex-
cellent and stable 100% 6 0.1% donor chimerism in
the CD14/15 subset at 1 month, with 99% 6 3.5%
chimerism at 24 months. The CD19 subset was mea-sured at 96% 6 1.0% at 1 month, rising to 99% 6
0.7% by 3 months and maintained at 99% 6 2.6% at
24 months. The CD3 subset achieved only a 78% 6
4.2% donor chimerism at 1 month, but rose to
87% 6 3.1% by 9 months and remained stable with
89% 6 0.7% chimerism at 24 months. Differences in
median donor chimerism were not statistically differ-
ent when analyzed by BM versus PBSC source.DLI
Four patients received a DLI for the following rea-
sons: 1 patient who underwent transplantation for
CML with active disease (unique patient number
[UPN] 1101) received a DLI at 4 months posttrans-
plantation due to a molecular relapse. After the DLI,
he achieved a remission and is alive and disease-free
73 months posttransplantation. Another patient with
monosomy 7 MDS (UPN 1306) required a DLI 7
Figure 1. Median donor chimerism. Engraftment percentage is the percentage of donor chimerism detected in whole blood (WB), CD31, CD14/151,
and CD191 subsets.
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though she did convert to full donor, she has since re-
lapsed and required an additional transplantation after
which she relapsed again and is currently alive with re-
lapsed disease. A patient with chronic granulomatous
disease (UPN 1126) had a slow but continued decline
in his donor chimerism and was given a DLI 19
months posttransplantation. He has a low but persis-
tent engraftment (26% donor in whole blood, 39%
in the granulocyte fraction) and is infection-free with
a 62-month follow-up. Last, a patient with hyper
IgM syndrome (UPN 1078) received a DLI 2 months
post–bone marrow transplantation (BMT) in order to
enhance clearance of CMV viremia in the setting of
continued lymphopenia.Immune Studies and Reconstitution
Before alemtuzumab, median lymphocyte subset
numbers were measured and available for 26 patients.
The CD3, CD4, CD8, CD19, and CD16/56 subsets
were 1597 6 186, 879 6 122, 618 6 63, 367 6 69,
and 1366 247  106cells/L, respectively. At a median
of 3 days (range, 2-6) after alemtuzumab administra-
tion, median absolute lymphocyte subset numbers
were available for 24 patients. The CD3, CD4, CD8,
CD19, and CD16/56 subsets were 1 6 0, 0 6 0, 0 6
0, 0 6 3, and 1 6 2  106cells/L, respectively.
Neutrophil recovery, characterized by an absolute
neutrophil count of.500 for 3 days, occurred at a me-
dian of 16 days (range, 10-22 days) for patients receiv-
ing PBSC versus a median of 18 days (range, 14-25
days; P 5 .03) for patients receiving BM. The median
time to T cell reconstitution was 6 months. The B cell
reconstitution was achieved at a median of 3 months.
Time to T or B cell reconstitution based on the stem
cell source was not statistically different.Toxicity and TRM
Nineteen patients had an infusion reaction to
alemtuzumab (20% grade 1, 34% grade 2). The most
common toxicity was grade 3 mucositis (43%), with
1 patient experiencing grade 4 mucositis. Only 1 pa-
tient developed SOS of moderate severity.
Two of 3 patients with graft failure/rejection died
after subsequent transplantations. Three additional
patients have died from transplantation-related causes,
resulting in a 1-year TRM of 9%6 5.2%. One patient
with Evans syndrome (UPN 1051) had refractory
thrombocytopenia and died of acute hemorrhage; a pa-
tient with adrenoleukodystrophy (ALD; UPN 1116)
having undergone a mismatched unrelated donor
(MMUD) PBSC transplant died of pulmonary invasive
aspergillosis 5 months after transplantation in the set-
ting of ongoing GVHD; and finally a patient with
HLH (UPN 1402) died from complications of pulmo-
nary hypertension.Viral Infections
Thirty-one patients were evaluable for CMV se-
rostatus before conditioning. The remaining 4 patients
were either incapable of producing Ab (hyper-IgM or
combined immunodeficiency) or their CMV testing
yielded an indeterminate result. Of the 14 evaluable
patients who were CMV seronegative, 1 patient who
received a graft from a CMV seropositive donor devel-
oped a detectable CMV viremia posttransplantation
(7%). Of the 17 evaluable patients who were CMV se-
ropositive, 12 patients had measurable CMV viremia
after transplantation (71%). Two of these patients re-
ceived a graft fromCMV seronegative donors, whereas
the remaining 9 patients had CMV seropositive do-
nors. Viremia was detected either by PCR or antigen
measurement, but no patients had evidence of active
Figure 2. Event-free survival. HCT indicates hematopoietic cell trans-
plant.
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and all had resolution of their viremia. Five of 35 pa-
tients (14%) were also found to have detectable EBV
after transplantation, but only 1 required treatment
with rituximab because of persistence of viremia. No
patient had evidence of posttransplantation lympho-
proliferative disease.
GVHD
Six patients developed acute GVHD (aGVHD) for
a cumulative incidence of 17% 6 6.6%. Four of these
patients had isolated grade I to II skinGVHD.One pa-
tient receiving a PBSC graft from an MMUD (UPN
1116) had GVHD of grade IV (stage 4 skin and stage
4 gastrointestinal). Another patient with ALD (UPN
1137) had aGVHD involving both skin (stage 2) and
liver (stage 2) after a MRD BMT. Two of these pa-
tients developed progressive onset cGVHD for a 2-
year cumulative incidence of 8%6 5.4%. One of these
patients (UPN 1388) resolved his symptoms by 9
months posttransplantation. Any GVHD was statisti-
cally more likely to occur with use of a PBSC graft in
comparison to a BM graft by 2-tailed Fisher exact
test (P 5 .02).
Progression/Relapse and Survival
Four of 30 patients with nonmalignant diseases ex-
perienced disease progression/recurrence for a 2-year
cumulative incidence of 16% 6 7.7%. A patient with
chronic active EBV infection and secondary HLH
(UPN 1395) is alive and well after relapse and subse-
quent transplantation. A patient with HLH (UPN
1331) relapsed and subsequently died after a second
transplantation due to fungemia in the setting of a thirdrelapse. A patient with paroxysmal nocturnal hemglo-
binuria (PNH; UPN 1211) developed recurrent aplas-
tic anemia but without a PNH clone and is well after
a second transplantation. A patient with ALD (UPN
1137) died of disease progression. Three of 5 patients
with malignancy experienced relapse resulting in a
2-year cumulative incidence of 60% 6 21.9%. Two
patients withMDS are alive after a second transplanta-
tion but only 1 is currently disease-free. The third
patient had a molecular relapse of CML after trans-
plantation but is in long-term molecular remission
after DLI.
At a median follow-up for living patients of 35
months (range, 15-85 months), the EFS (Figure 2)
for the entire cohort was 61% 6 9.0% with an EFS
of 66% 6 8.8% for patients with nonmalignant dis-
eases, and 40% 6 21.9% for patients with malignant
diseases. The OS (Figure 3) of the entire cohort was
78% 6 7.5%, with an OS of 73% 6 9.2% for the pa-
tients with nonmalignant diseases, and 100% for the
patients with malignant diseases.DISCUSSION
Wedescribe the results of a prospective trial of tar-
geted i.v. busulfan, fludarabine, and alemtuzumab in
a sizeable pediatric population. The incorporation of
alemtuzumab into the conditioning regimen was
well-tolerated. Although 54% of patients experienced
some acute toxicity to alemtuzumab infusion, none
was greater than grade II and all patients were able
to complete their scheduled doses. Nearly all patients
(94%) had some mucositis, although fewer than 50%
were more than grade II. Busulfan PK measurements
revealed average Css to be below 900 ng/mL, and
only 1 patient developed SOS that resolved with sup-
portive care.
In this study, 91% of patients achieved a durable
engraftment. This excellent rate of engraftment is
consistent with others who have begun to incorporate
alemtuzumab in their conditioning regimens achieving
\10% early graft failure [9,10,14]. Importantly, all 3
patients who rejected their graft underwent
transplantation for nonmalignant diseases and 2 of
the 3 received an MMUD graft. Despite this, 5 of the
7 patients who received an MMUD transplantation
engrafted successfully using alemtuzumab, whereas
none of the 3 patients undergoing an MMUD
transplantation in our previous trial using rATG
engrafted [5]. Although the engraftment rate in our
prior rATG study was only 79%, a Fisher exact test
failed to show a statistical difference between these tri-
als, likely resulting from the insufficient power
afforded by the relatively low patient numbers. A for-
mal case matched analysis was not performed because
the rATG study closed prematurely as it had reached
the stopping criteria for engraftment failure.
Figure 3. Overall survival. HCT indicates hematopoietic cell trans-
plant.
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nor chimerism was measured at regular intervals up to
2 years after transplantation in order to monitor for
late graft loss as well as for the risk of malignant relapse
[15]. Not only was engraftment improved in this study,
chimerism measures seemed to be quite good, with
only 2 patients requiring a donor lymphocyte infusion
for mixed donor chimerism. At 1 month, the median
percent donor chimerism was 99% in whole blood,
100% in the CD14/15 subset, and 96% in the CD19
subset. In contrast, the CD3 subset at 1 month only
achieved a 78%median donor chimerism,with a subse-
quent decline at 3 months to a median of 50%. How-
ever, a gradual rise followed and an 87%median donor
chimerism was reached at 9 months. Although the eti-
ology of this early CD3 dip has not been fully eluci-
dated, this phenomenon has been seen by others and
shows no ill effects [15]. At last follow-up, the majority
of patients treated in this study remained stable, with
mixed chimeras at a high median donor chimerism of
96% in whole blood.
With regard to immune studies, it was anticipated
that alemtuzumab would provide an effective elimina-
tion ofCD52 expressing cells. In fact, allmeasured lym-
phocyte subsets dramatically declined, although there
was more variability in the NK (CD16/56) and B cell
(CD19) subsets. Although there was no correlation be-
tween graft rejection and residual NK cell numbers in
this patient cohort, it is interesting to note that 2 of 3 pa-
tients with.20 106cells/L B cells after alemtuzumab
suffered graft rejection.We were unable to identify any
additional associations with B cell numbers within the
dataset. Because the numbers are too small to draw con-
clusions, attention to the role of B cells and Abs in graft
rejection may be prudent in future studies.Early experience with incorporating alemtuzumab
into transplantation conditioning regimens has pro-
duced concern for delayed immune reconstitution
[16]. However, our median time to T cell and B cell re-
constitution seems to be similar to what has previously
been reported [5]. Along with concerns for delayed T
cell recovery, others have shown significant rates of
CMV reactivation ranging from 50% to 85% in at-
risk patients [17,18]. Our seropositive patients had
a similar reactivation rate of 70.6%, but no patient
manifested CMV disease and all responded to
antiviral therapy. Perhaps because of partial donor B
cell depletion by residual alemtuzumab, our rates of
EBV reactivation were low. Only 5 patients had any
measurable EBV by PCR and none developed signs or
symptoms of posttransplantation lymphoproliferative
disease. Only 1 patient required therapy with
rituximab for persistent EBV viremia.
Although the main hypothesis for the replacement
of rATGwith alemtuzumab in this trial was to enhance
engraftment, we did find low rates of GVHD. Consis-
tent with other published data, this effect is thought to
be a result of alemtuzumab’s long half-life and perhaps
due to its targeting of dendritic cells involved in anti-
gen presentation [19]. Overall, a rate of 17% aGVHD
and 8% cGVHD seems favorable with regard to our
previous rATG study that resulted in 22% aGVHD
and 20% cGVHD.However, likely reflecting an insuf-
ficient power for comparison, a Fisher exact test failed
to show a statistically significant difference. It is known
that the presence ofGVHD ismultifactorial, including
the degree of donor HLA matching and stem cell
source. Our rates of GVHD are in keeping with others
who are now using alemtuzumab and achieving less
than 20% GVHD in patients receiving highly HLA-
matched BM stem cells [10,14]. Of the 16 patients in
our cohort receiving an MUD transplantation, only 3
(19%) experienced any GVHD. Similarly, of the 7
patients receiving an MMUD transplantation, only 2
patients (29%) developed GVHD in keeping with
studies using greater numbers of mismatched donors
of peripheral blood (PB) origin [9].
A high percentage (60%6 21.9%) of the 5 patients
withmalignancies relapsed, perhaps reflecting a higher
risk pool of patients. The patient with CML under-
went transplantation without molecular remission,
and all 3 patients with MDS were monosomy 7 posi-
tive. Alemtuzumab has been beneficial in the treatment
of CD52-expressing lymphoid malignancies [20] and
although the numbers are too small to draw conclu-
sions, it is possible that there is a differential effect in
our cohort due to the fact that myeloid rather than
lymphoid malignancies were included in this trial. It
is also possible that relapses were related to persistent
host chimerism in these patients. Further study will be
required to assess whether alemtuzumab is truly per-
missive of relapse in this setting.
Biol Blood Marrow Transplant 18:1656-1663, 2012 1663Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity RegimenCONCLUSION
The incorporation of alemtuzumab into a reduced
toxicity conditioning regimen of i.v. targeted busulfan
and fludarabine was well-tolerated and may enhance
engraftment rates and lower rates of GVHD as com-
pared with historical controls. Immune reconstitution
was not delayed and although viral reactivation rates
were high, none developed clinical disease. Graft rejec-
tion was associated with patients who had a nonmalig-
nant disease and received an MMUD graft, and future
studies should address this population in particular.
These results suggest that replacement of rATG
with alemtuzumab may improve engraftment as well
as decrease cGVHD rates without resulting in delays
in immune reconstitution.ACKNOWLEDGMENT
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